In:
International Journal of Cancer, Wiley, Vol. 137, No. 2 ( 2015-07-15), p. 372-384
Abstract:
What's new? While adjuvants can enhance immune responses induced by peptide and protein vaccines, in cancer immunotherapy, they fail to trigger the balanced, long‐lasting immunity that is needed for anti‐tumor protection. That limitation may be overcome with the development of synthetic RNA molecules as adjuvants, according to the present study. In a TC‐1 tumor mouse model, RNAdjuvant ® , a novel synthetic RNA with a polymeric carrier, significantly enhanced immune responses associated with the administration of peptide vaccine. Profound anti‐tumor effects were observed. The adjuvant acted locally, at the site of injection, without inducing systemic cytokine release.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2015
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink